Clinical Trial Update: Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation [Phase 2]

View source ↗

Summary

This document reports a Phase 2 trial update evaluating intermittent and maintenance erlotinib plus pemetrexed/carboplatin in advanced EGFR-mutant non-small cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• CARBOPLATIN (Carboplatin)
• Tarceva (erlotinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Lung, Carcinoma | Phase 2 | Status: UNKNOWN